Molecular imaging Theranostics of Neuroendocrine Tumors

Semin Nucl Med. 2023 Jul;53(4):539-554. doi: 10.1053/j.semnuclmed.2022.12.007. Epub 2023 Jan 7.

Abstract

Neuroendocrine neoplasms (NEN) are rare and heterogeneous tumors, originating mostly from the gastro-entero-pancreatic (GEP) tract followed by the lungs. Multidisciplinary discussion is mandatory for optimal diagnostic and therapeutic management. Well-differentiated NEN (NET) present a high expression of somatostatin receptors (SSTR) and can be studied with [68Ga]-DOTA-peptides ([68Ga]Ga-DOTANOC, [68Ga]Ga-DOTATOC, [68Ga]Ga-DOTATATE) PET/CT to assess disease extension and the eligibility for peptide receptor radionuclide therapy (PRRT). SSTR-analogues labelled with 90Y or 177Lu have been used since mid-90s for NET therapy. PRRT is now considered an effective and safe treatment option for SSTR-expressing NET: following the approval of 177Lu-DOTATATE by FDA and EMA, PRRT is now part of the therapeutic algorithms of the main scientific societies. New strategies to improve PRRT efficacy and to reduce its toxicity are under evaluation (eg, personalization of treatment schemes, the selection of the most suitable patients, improvement of response assessment criteria, optimization of treatment sequencing, feasibility of PRRT-retreatment, combination of PRRT with other treatments options). Recently, several emerging radiopharmaceuticals showed encouraging results for both imaging and therapy (eg, SSTR-analogues labelled with 18F, SSTR-antagonists for both diagnosis and therapy, alpha-labelling for therapy, radiopharmaceuticals binding to new cellular targets). Aim of this review is to focus on current knowledge and to outline emerging perspectives for NEN's diagnosis and therapy.

Publication types

  • Review

MeSH terms

  • Humans
  • Molecular Imaging
  • Neuroendocrine Tumors* / diagnostic imaging
  • Neuroendocrine Tumors* / radiotherapy
  • Positron Emission Tomography Computed Tomography*
  • Precision Medicine
  • Radiopharmaceuticals / therapeutic use
  • Receptors, Somatostatin / metabolism
  • Yttrium Radioisotopes

Substances

  • Yttrium-90
  • Yttrium Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Somatostatin